Replies to post #42625 on Cytogenix (fka CYGX)

[bigworld]

JJ: One point that has been made by me and other posters is that, given the short cash situation of the company and the fact that there is "so little (scientific) manpower", don't you think the company's money could have been better spent on a few extra scientists instead of the combined salaries and bonuses of MS, LW and FV over the last few years? How much further along would the company be? And how much higher would the share price be? Had they delayed their gratification just a little bit longer the net worth of the management team could have been much, much higher at this point in time, given the huge number of shares they own or have options to purchase. You have said that things can turn on a dime. I agree. Which is why time is of the essence. I have repeatedly begged the company to get on with it in regard to building a cGMP facility. I'm glad that is now in process (if the management upheaval does not jeopardize the anticipated funding.) But the announcement of it should have happened last March, which would have been 6 months after Aldevron told them that synDNA worked in vaccines. Had they started on the facility back then it would be near to completion and approval, and the share price would be 3 or 4 times what it is today. We would have continued the momentum that was started last December, instead of retreating to the current trading range which is over 50% lower than the yearly high. And to save you time, I'm not going to sell and bail at this point. A little new blood in the front office might be a shot in the arm for the company. I hope the construction goes well and on time. I hope more customers can be lined up for synDNA by the time the facility is completed, I'd love to see them use some of that 50 gram a day production capacity. I'd also like to see the place teeming with scientists in a few years, and the stock price get to $50 a share. And I'd also like you and everyone else on the board to have a Happy Thanksgiving.

[david02835]

Jimmie Joe, I think that you will find that most of us who are behind this investment but who are often critical of management (like myself) are not questioning the science or the procedures involved with running a biotech company. I think that the disatisfaction comes from feeling out of touch with the progress of the science and the feeling of vulnerability concerning the company's finances. Poor public relations is the problem here, not the future of synDNA if it turns out to be all we want it to be.
I appreciate your knowledge of biotech operations and the contributions of other posters who understand medicine and the biotech arena better than I, but I stand firm in my opinion that the company could be better managed. As I have alluded to in previous posts, I would be happier and more supportive of management if I could feel confident that the company can get the financing it needs in the proper way and if I had a clue as to the timetable for success (within a year say).
The info I was getting from the company came through a broker who said he was getting info from financial management at CYGX. I then proceeded to make an ass of myself by posting what I had heard on this board (i.e. agriculture, China, etc.) only to find out later that it was either baloney or way in advance of the potential deals. The info I was getting also came at a time that the company was "quietly" promoting PPOs. Hello!?
I sincerely hope that CYGX's management can reinvent itself to address my two major concerns or I will take your advice JJ and bail on the last business day of the year. Have a happy Turkey Day!